



Biofit

FOSTERING
INNOVATION
& TRANSFER

A 360° approach to source
early-stage innovations in Life Sciences

6th edition | Strasbourg

28th & 29th November 2017



#BioFIT
@BIOFIT_EVENT

CONTACT US

Nadège Joly | Event Communication Officer
njoly@eurasante.com | +33 (0)3 28 55 90 60

Organised by:



With the support of:



Financed by:





Biofit FOSTERING
INNOVATION
& TRANSFER

STRASBOURG 2017 - FRANCE

at a glance



Etienne Vervaecke,
General Commissioner
of BioFIT

«Year after year, BioFIT has emerged as the leading partnering event in Europe to source early-stage innovations and collaborative research capacities in Life Sciences.

We are pleased to see the development of the event as a marketplace for pre-seed, seed and Series A investment in Life Sciences over recent years.

During this 6th edition of BioFIT, you will be more than 1,000 delegates from 30 countries representing large companies, medium-sized businesses, start-ups as well as tech transfer organisations, academics and investors. We look forward to seeing many high-potential collaborations generated during the convention.

Don't miss also this edition's conferences, with international high-level speakers, which represent the perfect opportunity to gain insight and discover the latest industry trends.

Now it's time for us to let you take the control of your event. We wish you productive and enjoyable two days, with a variety of meetings and partnership opportunities.»

Key figures



1,200

Delegates



30+

Countries
represented



2,500

One-to-one
meetings
(in 2016)



800

Licensing
opportunities
(in 2016)



15

Conferences
and roundtable
discussions



80

Speakers



100

Exhibitors

TABLE OF CONTENTS

BioFIT, a tailor-made event for the Life Sciences actors.....	4
The assets of an alternation between Lille and Strasbourg.....	6
4 main activities in details	
One-to-one meetings.....	7
Conferences.....	8
Presentation sessions.....	11
Exhibition.....	12
Hosted Events	
R&D Dating for Animal Health and Innovation.....	13
LabEx Medalis Conference.....	14
Open Data Challenge.....	15
Organisers/Sponsors/ Supporters / Media Partners.....	16



BioFIT, a tailor-made event for the Life Sciences actors

BioFIT is the leading partnering event in Europe for technology transfer, academia-industry collaborations and early-stage innovation in the field of Life Sciences. In addition, BioFIT is the marketplace for preseed, seed and Series A investment in Life Sciences.

BioFIT gathers in one place all the academic and industrial actors who aim both to develop partnerships between public and private and commercialise early-stage assets from the academic sector or start-ups. During two days, attendees have access to four main activities: **One-to-one meetings, conferences, presentations sessions and exhibition.**

Many Life Science leaders as Lilly, Roche, Merck, MSD, Boehringer Ingelheim, Bayer, Johnson&Johnson, Trianni, Sanofi or Pfizer attend BioFIT 2017. In total, more than 800 licensing opportunities and more than 2,500 one-to-one meetings were brought by the business convention in 2016. Moreover, the meetings can also be held in the exhibition area which will gather more than 100 exhibitors this year.

The Start-ups Slams, a flagship activity of BioFIT, will **highlight young companies**. 20 entrepreneurs will present their project in front of an audience and a panel of experts. A real speed-mentoring exercise will be realised and will provide visibility to potential investors and industrial partners.

Always with a view to bringing the academic and industrial sectors closer together, BioFIT includes licensing opportunity presentations.

These sessions will be the opportunity for academics and tech transfer organisations to **present their technology** ready-to-be-licensed.

More information about the activities page 7



David Wehner
Venneos GmbH

"BioFIT is a great platform to exchange with all relevant players in the field on a European level. Interesting talks, great inspiration & good networking!"

One event - Four activities



ONE-TO-ONE MEETINGS

Build and develop innovation and business collaborations



PITCH SESSIONS

Identify and promote innovative projects and technologies



CONFERENCES AND ROUNDTABLE DISCUSSIONS

Gain insight and discover the latest sector trends



EXHIBITION

Highlight your company with other innovators in the Life Sciences sector



Stefan K. Nilsson

CEO and founder of Lipigon Pharmaceuticals

"Interaction is indeed key and professional partnering events like BioFIT are important for these interactions."



Cécile Théard-Jallu

Partner Attorney, De Gaulle Fleurance & Associés

"Meeting actors from the Life Sciences sector and listening to them talk about their projects is always fruitful for a legal advisor as it helps to further understand these projects and more generally, sectorial tendencies in a concrete way."



Ron Newbold

Pfizer Worldwide Research and Development

"Pfizer is now quite active in supporting dozens of partnerships globally (we have funded well over 100 in the past 4 years) and are also making seed investments into new companies as they are spun out of universities."



Kevin McBride

Vice-president research, AmorChem

"The one to one partnering session system is truly stimulating."

The assets of an alternation between Lille and Strasbourg

It's the second time that the city of Strasbourg hosts BioFIT (first one in 2015).

European metropolis of Strasbourg and the Grand Est Region are a high place of the Life Sciences located in the heart of Europe, at the cross-border region characterised by a strong culture of Franco-German-Swiss cooperation. The BioValley region concentrates **a unique density of actors of excellence in Life Sciences and Health** with no less than 7 Nobel Prize winners, 3 leading universities, global-renowned research institutes and more than 600 companies, ranging from innovative start-ups to pharmaceutical giants.

The cooperation between an economic development agency (Eurasanté), two competitiveness clusters (Alsace BioValley and the Nutrition Health Longevity Cluster) and a French TTO (SATT Conectus) for the organisation of such an event is a good example of cluster collaboration. This unique combination serves the regions' and French cluster's competitiveness.

The next edition of BioFIT will be held on 4th and 5th December 2018, in Lille (France).



STRASBOURG AND THE GRAND EST REGION:

HOTSPOT FOR LIFE SCIENCES INNOVATIONS

The heartbeat of the Rhine basin, Strasbourg occupies a strategic position at the crossroads of France, Germany and Switzerland. The Grand Est Region, located in the center of Europe, is defined by cross-border relationships. The region and city's growth is driven by an innovative economy and world class universities which work closely with the industry. Strasbourg is located in the famous French-German-Swiss BioValley, which is host to almost half of the world's leading pharmaceutical companies (Lilly, Sanofi, Novartis...). It is a unique concentration of actors of excellence in Life Sciences and Health. Renowned companies, world-class research institutes and scientific award winners share their expertise in areas such as medical and surgical robotics, minimally invasive surgery, genetics and molecular and cell biology, neuroscience, chemistry or biomaterials. All these players benefit from many advantages of an ecosystem boosted by Alsace BioValley, a world-class cluster which actively supports therapeutic innovation projects, whether they are related to new drugs or medical technologies.

The 4 main activities in details

One-to-one meetings

The business convention helps attendees to organise their one-to-one meetings with their future project partners, in order to **accelerate innovation and get financed**. This activity is powered by **partneringONE** a service of EBD GROUP which provides the online partnering platform which allows attendees to schedule their meetings with the other participants before the event.

BioFIT attracts top international executives from established and emerging biotech companies, pharmaceutical/ diagnostic companies, TTOs and academia, research institutions, institutional and private investors, services and consulting companies...

Who are the BioFIT participants?



30% TTOs / Research institutions / Academics



15% Preclinical CROs



20% Pharma / Diagnostic companies



10% Pre-seed, seed and Series A investors



20% Emerging biotech companies



5% Professional services / Consulting / Law firms




Fusion Antibodies
@finaAntibodies

Meet our Fusion team at #BioFIT 2017 in Strasbourg on 28-29th November. With the highest attending rate of academics, TTOs & research institutions, #BioFIT is the place where academia-industry collaborations get started! Get in contact to set up a meeting. ow.ly/XWst30grnm9


Domainex
@Domainex_UK

@Domainex_UK will be in Strasbourg next week, for #BioFIT 2017 run by @BIOFIT_EVENT. Come along and speak with us at stand A6 - we look forward to seeing you there. #drugdiscovery #partnering #biotech buff.ly/2iExiol



Hovione
@HovioneGroup

Let's talk about challenges in #LifeSciences! Next week, Hovione is attending #BioFIT 2017 in #Strasbourg. Meet with us to learn about our innovative solutions. #earlystage #technologytransfer #particleengineering



Aptuit
@aptuit

Next week we'll be in #Strasbourg for the #BioFIT 2017 congress. Our expert, Francesca Sadler, will be on hand to discuss any requirements you have. Get in contact to arrange a meeting. (aptu.it/2iZn7u5) @BIOFIT_EVENT



Sciomics GmbH
@sciomics

Meet us at our BioFIT booth in Strasbourg on the 28th – 29th November to discuss how protein and phosphorylation profiling may speed up your projects. Looking forward to seeing you there.

Check out the 2017 Participants online: bit.ly/2xp8wRA



Conferences and roundtable discussions

BioFIT 2017 is honoured to receive the support of a prestigious Steering Committee composed of 27 renowned international experts who ensure the relevance of the BioFIT conference programme and contribute to the recruitment of the Speakers. The Steering Committee is composed of:

PHARMA, BIOTECH



Cédric Barriere

DIRECTOR, EXTERNAL INNOVATION
ONCOLOGY, EXTERNAL SCIENCE
AND PARTNERING, **SANOFI** [FR]



Maria Bobadilla

SENIOR DIRECTOR, EXTENDING
INNOVATION NETWORK,
ROCHE [CH]



Adrian Carter

CORPORATE VICE PRESIDENT AND
GLOBAL HEAD OF DISCOVERY
RESEARCH COORDINATION,
BOEHRINGER INGELHEIM [DE]



Sami Chtourou

DIRECTOR OF TECHNOLOGY
PLATFORMS AND INNOVATION,
LFB [FR]



Florence Dal Degan

R&D INNOVATION SOURCING
DIRECTOR, **NOVO NORDISK** [DK]



Guy Helin

CEO, **SYNGULON** [BE]



Stephan Lensky

CHIEF OPERATING AND CHIEF
BUSINESS OFFICE, **EPIMAB**
BIOTHERAPEUTICS [CN]



Sabrina Lesage

STRATEGIC ALLIANCES MANAGER,
Pfizer [FR]



Pascal Raoul

SCIENTIFIC AND INNOVATION
DIRECTOR, **CEVA** [FR]



Frédéric Scaerou

DIRECTOR, SCIENTIFIC
AFFAIRS ONCOLOGY,
IPSEN INNOVATION [FR]



Nadine Weisslinger-Darmon

MEDICAL DIRECTOR SPECIALTY
PRODUCTS, CLINICAL RESEARCH
AND ACADEMIC ALLIANCES, **GSK** [FR]

ACADEMIA, TTOs



Hervé Ansanay

OPERATIONS DIRECTOR,
SATT AXLR [FR]



Garold Breit

DIRECTOR, TECHNOLOGY
BUSINESS DEVELOPMENT,
CITY OF CHARLESTON [USA]



Nicolas Carboni

PRESIDENT, **SATT CONECTUS**
ALSACE [FR]



Jean-Luc Chagnaud

HEALTHCARE BUSINESS
DEVELOPMENT MANAGER
& INTELLECTUAL PROPERTY
MANAGER, **AQUITAINE SCIENCE**
TRANSFERT [FR]



Lilla Farkas

HEAD OF THE OFFICE OF THE
MANAGING DIRECTOR, RESEARCH
COORDINATOR, **MPI-CBG**,
MAX PLANCK INSTITUTE OF
MOLECULAR CELL BIOLOGY AND
GENETICS [DE]



Matthieu Fisichella

LIFE SCIENCES EXPERT,
SATT NORD [FR]



Esther Lange

INDUSTRY LIAISON MANAGER,
ASCENION [DE]

ASSOCIATIONS, CLUSTERS, INVESTORS & LAW FIRMS



Claude-Alain Cudennec

GENERAL DIRECTOR, **AFSSI -**
THE FRENCH ASSOCIATION OF
OUTSOURCING AND INNOVATIVE
COMPANIES [FR]



Barbara Freischem

MANAGING DIRECTOR, **EBE -**
EUROPEAN BIOPHARMACEUTICAL
ENTERPRISES [BE]



Jean-Louis Hunault

PRESIDENT, **SIMV - THE FRENCH**
ASSOCIATION OF THE ANIMAL
HEALTH INDUSTRY [FR]



Sara Nunez-Garcia

PRINCIPAL,
SOFINNOVA PARTNERS [FR]



Marco Pintore

GENERAL MANAGER,
ALSACE BIOVALLEY [FR]



Christian Policard

MEMBER OF THE BOARD,
CHAIRMAN OF THE BUSINESS
DEVELOPMENT SUB-COMMITTEE,
FRANCE BIOTECH [FR]



Emilie Royere

DIRECTOR, **EUROBIOMED** [FR]



Cécile Theard-Jallu

PARTNER ATTORNEY, **DE GAULLE**
FLEURANCE & ASSOCIÉS [FR]



Etienne Vervaecke

GENERAL MANAGER,
EURASANTE & NHL CLUSTER [FR]

The BioFIT conference programme is designed in three tracks:

- Track 1** New players involved in innovation in the health sector
- Track 2** Nurturing and licensing early-stage assets
- Track 3** Bioentrepreneurs' challenges at pre-seed, seed and Series A stages

Plenary Session

28th Nov. 11.30 am - 1.00 pm | CURIE ROOM

HOW CAN WE OVERCOME THE SHORTAGE OF BIOENTREPRENEURS IN EUROPE?

Europe is currently benefiting from a unique level of academic research and access to equity investment has also improved. Despite this, Europe is still lacking bioentrepreneurs. How can we attract entrepreneurs in Life Sciences? How to convince talented scientists to become entrepreneurs? Can the support from technology transfer offices, incubators and early investors provide sufficient mentorship and a wide enough network?



MODERATOR

John Hodgson

DATA EDITOR, INFORMA

David Wehner

MANAGING DIRECTOR,
VENNEOS

Toby Reid

MANAGING DIRECTOR,
BIOCITY

Philippe Pouletty

FOUNDER,
TRUFFLE CAPITAL

Alain Wagner

RESEARCH DIRECTOR,
CNRS

Valentin Lubbe

PROGRAM MANAGER,
NORDIC MENTOR NETWORK
FOR ENTREPRENEURSHIP

Dick Hoogenberg

PARTNER, EY

Throughout the conferences, 80 international speakers including Andrew Fried (IBM, UK), Grit Zahn (Eternygen, DE), Peter Opdam (MSD Animal Health, NL), Tony Hickson (Imperial Innovations, UK), Duncan Holmes (GlaxoSmithKline, UK), Nathalie ter Wengel (Pfizer, NL), James Peyer (Apollo Ventures, DE), Sofia Ioannidou (Edmond de Rothschild Investment Partners, FR), Sascha Berger (TVM Life Science Management, DE) and Klaus Mendla (Boehringer Ingelheim, DE), will discuss around the issues and the trends of the Life Science field.



Garold Breit,
Director, Technology Business Development
City of Charleston

"I recognize BioFIT's significant value as an important meeting place for investors, scientists and entrepreneurs. Quite simply, our team attends 8 Conferences every year and we find that BioFIT is uniquely productive."



Discover the conferences in the programme or online bit.ly/2yqjof1

AGENDA DAY ONE

Tuesday 28th November 2017

WELCOME COFFEE				
Conferences and roundtable discussions		Presentation sessions	Hosted Event	Partnering
8.30 am 9.30 am	<div>MADRID 4 ROOM</div> <div>Shared risk or competition for emerging assets: How can we optimise pharma-VC relationships?</div>	<div>MADRID 3 ROOM</div> <div>How can collaborations in rare diseases be an asset in a highly competitive and fast moving market?</div>	<div>ROME 5 ROOM</div> <div>Translational research at Medalis: From lab to biotech</div>	<div>Biofit</div> <div>One-to-one meetings</div> <div>&</div> <div>EUROPEAN SOCIETY FOR ANIMAL HEALTH AND INNOVATION</div> <div>R&D dating for animal health and innovation</div>
NETWORKING BREAK				
11.00 am 11.30 am	How can we overcome the shortage of bioentrepreneurs in Europe? CURIE ROOM - 1 st FLOOR			
11.30 am 1.00 pm				
LUNCH				
1.00 pm 2.30 pm	<div>MADRID 4 ROOM</div> <div>Exploring the growing relationship between pharma, digital health companies and data providers</div>	<div>MADRID 3 ROOM</div> <div>Assessing the opportunity for licensing early-stage projects</div>	<div>ROME 5 ROOM</div> <div>Early projects, early opportunity: Find your match</div>	<div>Biofit</div> <div>One-to-one meetings</div> <div>&</div> <div>EUROPEAN SOCIETY FOR ANIMAL HEALTH AND INNOVATION</div> <div>R&D dating for animal health and innovation</div>
2.30 pm 4.00 pm				
NETWORKING BREAK				
4.00 pm 4.30 pm	<div>MADRID 4 ROOM</div> <div>How are focused therapeutic funds becoming increasingly important at pre-seed, seed and Series A stages?</div>	<div>MADRID 3 ROOM</div> <div>Workshop: A closer look at early-stage collaborations in the UK</div>	<div>ROME 5 ROOM</div> <div>Nature and nurture of an Academic drug discovery Centre</div>	
4.30 pm 6.00 pm				
6.30 pm				

AGENDA DAY TWO

Wednesday 29th November 2017

WELCOME COFFEE				
Conferences and roundtable discussions	Presentation sessions	Partnering		
<div>MADRID 4 ROOM</div> <div>How to keep the founding scientists committed?</div>	<div>MADRID 3 ROOM</div> <div>How are collaborations key to improve innovation in metabolic diseases?</div>	<div>INNOV AREA EXHIBITION HALL</div> <div>Start-up Slams</div> <div>Oncology/Immunology</div> <div>STIpe Therapeutics</div> <div>Theraporvir Elthera</div> <div>Chromatlys</div>	<div>Biofit</div> <div>One-to-one meetings</div>	8.30 am 9.00 am
<div>NETWORKING BREAK</div>				
10.30 am 11.00 am			<div>Biofit</div> <div>One-to-one meetings</div>	
11.00 am 12.30 pm	<div>MADRID 4 ROOM</div> <div>Where will European pre-seed, seed and Series A investment go in 2018?</div>	<div>MADRID 3 ROOM</div> <div>How can animal and human innovation / applications be mutually beneficial?</div>	<div>INNOV AREA EXHIBITION HALL</div> <div>Licensing Opportunity Presentations</div> <div>Neurology</div> <div>Vascular/Metabolic</div>	
<div>LUNCH</div>				
12.30 pm 2.00 pm				
2.00 pm 3.30 pm	<div>MADRID 4 ROOM</div> <div>Are venture philanthropy and trusts emerging in the initial stages of funding?</div>	<div>MADRID 3 ROOM</div> <div>How can TTOs increase their role in the early development of spin-offs?</div>	<div>INNOV AREA EXHIBITION HALL</div> <div>Start-up Slams</div> <div>Research tools/Therapeutic delivery</div> <div>Mecachips DyNAbind</div> <div>SimplicityBio Renovos</div> <div>Ageing / Pain</div> <div>Innapain</div> <div>PRAGMA Therapeutics</div> <div>Reminisces</div>	<div>Biofit</div> <div>One-to-one meetings</div>
<div>NETWORKING BREAK</div>				
3.30 pm			<div>Biofit</div> <div>One-to-one meetings</div>	
4.00 pm 4.30 pm	<div>MADRID 4 ROOM</div> <div>How can we define a mutually beneficial collaboration between an academic institution and a resulting spin-off?</div>	<div>MADRID 3 ROOM</div> <div>How can we define a mutually beneficial collaboration between an academic institution and a resulting spin-off?</div>	<div>INNOV AREA EXHIBITION HALL</div> <div>Award ceremony of the most innovative start-up</div>	<div>Biofit</div> <div>One-to-one meetings</div>
4.30 pm 5.00 pm	<div>CLOSING COFFEE BREAK</div>			
6.00 pm				

- Track 1: New players involved in innovation in the health sector
- Track 2: Nurturing and licensing early-stage assets
- Track 3: Bioentrepreneurs' challenges at pre-seed, seed and Series A stages

Presentation sessions

Start-up Slams

The Start-up Slams are presented by entrepreneurs who have created an innovative company (less than 5-year-old or to be created). During the presentations, the selected candidates will present their project to potential partners and investors who could support their company and receive feedback and advice (speed-mentoring) from a panel of experts.



Michèle Ollier,
Co-founder and Partner
Medicxi

"To be sure to raise capital, the first and most important step is to deliver your project to business and science experts. Companies should ask the experts to be very critical, as sweet talk is not constructive. Multiplying these meetings with the right people will help identify the project's real strengths but also its weaknesses, which is key. Advance awareness of these axes of progress will make the project much stronger and credible."

PANEL OF EXPERTS:

Maria Bobadilla

SENIOR DIRECTOR, EXTENDING
INNOVATION NETWORK,
ROCHE

Esther Lange

INDUSTRY LIAISON
MANAGER, ASCENION

Garold Breit

DIRECTOR, TECHNOLOGY
BUSINESS DEVELOPMENT,
CITY OF CHARLESTON

Stephan Lensky

CHIEF OPERATING
& CHIEF BUSINESS OFFICE,
EPIMAB BIOTHERAPEUTICS

Florence Dal Degan

R&D INNOVATION
SOURCING DIRECTOR,
NOVO NORDISK

Cécile Theard-Jallu

PARTNER ATTORNEY,
DE GAULLE FLEURANCE
& ASSOCIÉS

Joel Yao

ASSOCIATE,
SOFINNOVA PARTNERS

Christopher de Souza

DIRECTOR,
BROADVIEW VENTURES

More details in the programme or on www.biofit-event.com/agenda-startup-slams/

Licensing Opportunity Presentations

The Licensing Opportunity Presentations are presented by TTOs, universities or related structures that have ready-to-be-licensed technologies.

The aim of this session is to foster alliances and business development opportunities on innovative projects stemming from academia.



Julie Proft
Institute of Organic Chemistry and
Biochemistry of Prague

"BioFIT is for us a good platform to meet with potential partners and we have made successful connections in the past years. This year, we, in particular, are seeking for commercial partners to out-license and/or co-develop our technologies."

More details in the programme or on www.biofit-event.com/presenting/licensing-opportunity-presentations/

If the Business Convention is at the heart of the event, the exhibition is also a key part of BioFIT. It has quintupled its attendance since 2010, starting with 20 international exhibitors and co-exhibitors to grow to 100 this year, which shows the actors' wish is to be increasingly present and visible.



EXHIBITOR LIST

3M PURIFICATION B3
ADIS F4

AFSSI

ASSOCIATION FRANÇAISE
DES SOCIÉTÉS DE SERVICES
ET D'INNOVATION F1-E4
CLOA F1-E4/3
DRUGABILIS F1-E4/4
ITEC SERVICES F1-E4/5
RD-BIOTECH F1-E4/1
SMALTIS F1-E4/2

ALCAMI CORPORATION A1

ALSACE BIOVALLEY

ALSACE BIOVALLEY E2-D8
AÉRIAL E2-D8/1
BIONEXT E2-D8/2
CENTRE EUROPÉEN
D'ÉTUDE DU DIABÈTE E2-D8/8
CONFARMA FRANCE E2-D8/4
DYNACURE E2-D8/6
HARMONIC PHARMA E2-D8/7
KSIUNK E2-D8/9
NANOTRANSMED E2-D8/3
PHENOMIN-ICS E2-D8/5

ARTES BIOTECHNOLOGY F2
ARVATO C8

ATLANPOLE BIOTHERAPIES

ATLANPOLE BIOTHERAPIES D3
BIOGENOUEST C11
ID2SANTÉ D3

BACCINEX SA

BACHEM C7
BIOTRIAL F3
CELL&CO BIOSERVICES A8
CIDETEC NANOMEDICINE B6
CITOXLAB E5
CYTENA GMBH E6
CZECHEINVEST E3
DELPHARM BIOTECH B8
DOMAINEX A6
EATRIS C38
ENTERPRISE LITHUANIA B10
E-PHY-SCIENCE B13
ERDYN B4
EU-JAPAN CENTRE FOR
INDUSTRIAL COOPERATION E7
RESEARCH GMBH A5
FINDMED D6
FUTURE WORLDS B11
GENOSAFE B12
IFREMER C1
INFICURE BIO E8
INOVIEM SCIENTIFIC A3
KITOS BIOTECH, SRLS A7

LILLE NORTHERN

FRANCE BIOCLUSTER

EURASANTÉ D7
NUTRITION HEALTH
LONGEVITY CLUSTER D7
AMYLGEN D7/1
BOOST4HEALTH D7/3
GENOSCREEN D7/4
HCS PHARMA D7/6
INNOBIOCHIPS D7/2
-SENCECT D7/5

MACO PHARMA D2
MAGLE CHEMSWED B5

MEDICALPS - THE HEALTH-TECH

CLUSTER OF THE FRENCH APLS
ARAYMONDLIFE D1-C9
ECRINS THERAPEUTICS SERVICES D1-C9
-RHEONOVA D1-C9
MICROSYNTH AG B2
NEURATRIS C3
NOVA BIOMEDICAL A4
OCR D9
OVH DIGITAL LAUNCH PAD E1
PHARMA LOGISTICS CLUB C12
PORSOIT D4
PRECI PLATFORM D9
PROGINASE C2

R&D DATING FOR ANIMAL HEALTH

AND INNOVATION - SIMV

SIMV-FRENCH ASSOCIATION OF
ANIMAL HEALTH INDUSTRY C13
INSTITUT CARNOT FRANCE
FUTUR ELEVAGE C14
VET+ FOUNDATION,
SPANISH TECHNOLOGY
PLATFORM FOR ANIMAL HEALTH D5

RÉSEAU SATT

AQUITAINE SCIENCE TRANSFERT C6-B15
AXLR C6-B15
OUEST VALORISATION C6-B15
PULSALYS C6-B15
RÉSEAU SATT C6-B15
SATT CONECTUS C6-B15
SATT GRAND CENTRE C6-B15
SATT GRAND EST C6-B15
SATT NORD C6-B15
-SATT SUD-EST C6-B15
SANTAKA VALLEY ASSOCIATION B9
SCIENCE ME UP C10
SCIOIMICS-ENABLING
PRECISION MEDICINE C15
SOLADIS B7
SYNAGING SAS C4
VEOLIA WATER TECHNOLOGIES D10
VIROSCAN3D B1
XPRESS BIOLOGICS B14

INNOV'AREA

VASCULAR | METABOLIC
APTAMIR ia7
CARDIOR PHARMACEUTICALS ia2
EMOSIS ia6
-OP2LYSIS ia1
VACCINOLOGY | VIROLOGY
PAR'IMMUNE ia4
VAXINANO ia8
-VIRELIEVE ia3
ONCOLOGY | IMMUNO-ONCO
CHROMALYS ia19
ELTHERA ia15
STIPE THERAPEUTICS ia17
-THERANOVIR ia18
RESEARCH TOOLS
DYNABIND ia5
MECACHIPS ia9
RENOVOS ia11
-SIMPLICITYBIO ia10
AGEING | PAIN
INNOPAIN ia12
PRAGMA THERAPEUTICS ia16
-REMINISCENCES ia20

Hosted Events

The R&D Dating for Animal Health and Innovation



BioFIT hosts the 3rd edition of the “R&D dating for Animal Health and Innovation”, initiated by the French association for the animal health industry (SIMV), on 28th and 29th November 2017 in Strasbourg.

Today, public-private and private-private partnerships are thought to be the needed leverage for innovation. Hence, the SIMV (the French association for the animal health industry) launched the “R&D dating for Animal Health and Innovation” which aims at initiating high-level exchanges between the research departments of the veterinary medicine and diagnostics industry and public research, as well as biotechnology companies (start-ups).

By enabling face-to-face encounters, the event will enhance the visibility of cutting-edge research in France and in Europe, encourage investments and lead to therapeutic innovation.

29th Nov. 11.00 am - 12.30 pm | SALON MADRID 3 ROOM

How can animal and human innovation/applications be mutually beneficial?

We will address innovation opportunities and pitfalls to be avoided when engaging in collaborations between human health players and animal health actors. Which are the conditions to be gathered to make innovation happen? Which types of collaborations can be put in place? What are the successful examples? What are the limits to these collaborations?

MEET SIMV AT BOOTH C13

Organised by:



Hosted Events

LabEx Medalis Conference



The Medalis drug research centre is a «Laboratory of Excellence» (Labex) created in July 2011 as part of the French «Investments for the Future» programme. It is a member of «Initiatives of excellence» (IDEX) in the University of Strasbourg. Its aim is to develop innovative drugs for the treatment of cancer or inflammation.

Medalis' strengths:

A unique network of 200 researchers and PhDs from 11 research teams focused on chemistry and biology whose excellency has been certified by the national «Agency for Evaluation of Research and Universities», currently «Haut Conseil de l'Évaluation de la Recherche et de l'Enseignement Supérieur».

State-of-the-art scientific equipment, such as platforms dedicated to virtual and microfluidic screening.

A stimulating environment: Medalis is based in the heart of Europe, in Strasbourg, where the research institutes are internationally renowned for their achievements in the fields of pharmacology and biotechnology.

Medalis researchers have access to a highly competitive research environment provided by Strasbourg University and national research institutions like CNRS or INSERM. Moreover, Strasbourg University was awarded for the excellence of its supported projects (including Medalis) and has received an «Initiative of Excellence» funding from the French Investment for the Future Programme.

28th Nov. | ROME 5 ROOM

SESSION 1: 9.30 - 11.00 am

Translational research at Medalis: From lab to biotech

SESSION 2: 2.30 - 4.00 pm

Early projects, early opportunity: Find your match

SESSION 3: 4.30 - 6.00 pm

Nature and nurture of an academic drug discovery centre

Hosted Events

Challenge Open Data



The Open Data Challenge is a call for projects that encourages open innovation initiatives between companies and public institutions facing digital challenges and SMEs which provide innovative technologies. Launched during summer 2017, the first phase of this project ended in September 2017 with the selection of three companies for their innovative solutions aimed at resolving the EFS's (French Blood Agency) blood forecasting needs.

The selected companies competing for the challenge are Kaduceo, Open DataSoft and Open Health.



Award Ceremony | **28th Nov.** 5.30 pm | BOOTH D7 (Exhibition Hall)

«EFS' participation at the Open Data Challenge was obvious considering the interesting theme and regarding the opportunity to collaborate with qualified start-ups. This initiative, centred on Open Data will allow us to enhance our ability to adapt to upcoming evolutions and therefore, be as efficient as possible.»

Eric Resch, Haemovigilance and distribution officer, **EFS**

«Through our Digital Launch Pad Program, launched 2 years ago, we have helped hundreds of companies to develop their business activities. An increasing number of our clients work in the health sector and we are providing them with the necessary data storage services. We are delighted to share the type of expertise at the Open Data Challenge.»

Guillaume Fillière, Digital Launchpad Programme Manager, **OVH**

Organised by:



In collaboration with:



In partnership with:



Financed by:



ORGANISED BY



Eurasanté is an incubator, a technology transfer facilitator and a leading cluster in the fields of biotech, nutrition and healthcare in the Northern France region. It assists French and foreign companies, entrepreneurs, scientists and clinicians with their innovation and development projects. The regional network includes more than 1,000 companies working in Life Sciences and Healthcare. It benefits from an exceptional location in the heart of Europe (near Paris, London and Brussels). The Life Sciences sector in the Northern France region gathers a total of 28,000 employees. Eurasanté also promotes the Eurasanté Bio-business Park which hosts 7 hospitals, 4 universities, 7 specialised schools, more than 150 companies and 50 laboratories. In addition, Eurasanté organises 4 international partnering events annually, which aim to increase and improve interactions between academia and industry and encourage additional innovative sector collaborations: BioFIT, MedFIT, NutrEvent and AgeingFit.



As a French world-class cluster dedicated to therapeutic innovations, Alsace BioValley is the one-stop contact to optimise any R&D development or business project in Europe, both in drug development and medical technologies. Located in Eastern France, part of the famous French-German-Swiss BioValley and with a unique concentration of international life sciences & healthcare players, Alsace BioValley helps any Life Sciences & Healthcare companies or academics interested in new projects and partnerships in Europe to search outstanding scientific or industrial partners to develop very innovative R&D projects, to find the best innovative technology, patent or scientific expertise, or set up and locate in Eastern France. Alsace BioValley has also agreements with BioWin (Wallonia), CQDM (Quebec), JBA (Japan Bioindustry Association), Biopro (Germany) and Basel Area (Switzerland).



The Nutrition Health Longevity (NHL) Cluster is a dynamic network focusing on the main issues at the crossroads of health, biotechnology and nutrition. The NHL Cluster aims to federate public and private partners around R&D projects, which lead to innovative products in the fields of nutrition and health. The NHL Cluster's activity is centred on the prevention and treatment of life-style related diseases, such as metabolic and cardiovascular pathologies, neurodegenerative and inflammatory bowel diseases. Its objective is to gather and support players from the health and food sectors in the design, the development and financing of their future products and processes.

IN COLLABORATION WITH



FINANCED BY



GOLD SPONSOR



BRONZE SPONSORS



CONTRIBUTING
SPONSORS



SUPPORTERS



MEDIA PARTNERS

actulabo

**BIOTECH
GATE**
GLOBAL DATABASE


LABIOTECH.eu
 The European Biotech News Website

BIOTECH.INFO
 La lettre des biotechnologies 3.0

Biowebspin


**European
Biotechnology**
 Life Sciences and Industry Magazine


**La gazette
DU LABORATOIRE**

 GlobalData.

HOSPIMEDIA
 L'actualité des territoires de santé


innoget
 Innovation through open innovation

INNOVATION
 Review

[LSF] Life-Sciences-France.com
 The French Life Sciences Web Portal


MedNous
 Opportunities in European Medical Innovation


**PHARMA
BOARDROOM**


**Pharmaceutical
-Tech.com**
 A Global Leader in B2B Services

Plattform
Life Sciences

Any question?

CONTACT US

Nadège Joly | Event Communication Officer
 njoly@eurasante.com | +33 (0)3 28 55 90 60



Save the Date

4th & 5th
Dec. 2018

7th
edition

LILLE,
France



Biofit

FOSTERING
INNOVATION
& TRANSFER

LILLE 2018 - FRANCE

A 360° approach to source
early-stage innovations in Life Sciences

www.biofit-event.com

 @BIOFIT_EVENT